title: Effect of lipoxin A4 on myocardial ischemia reperfusion injury following cardiac arrest in a rabbit model.
abstract: In the present study, we investigated the effect of lipoxin A4 on myocardial ischemia-reperfusion injury (IRI) following cardiac arrest (CA) in a rabbit model. Lipoxin A4 is a metabolite of arachidonic acid in the eicosanoid, it is called "brake signal" for its anti-inflammatory activity. Some inflammatory factors (IL-1β, IL-6, TNF-α, and IL-10), NF-κB p65, infarct ratios, apoptotic index, cardiac troponin I (cTnI), hemodynamic and myocardial structures were measured or observed in different groups. Lipoxin A4 inhibits the expression of IL-1β, IL-6, and TNF-α, the values of the infarct ratios, apoptotic index, the level of serum cTnI and NF-κB p65. Meanwhile, it improves the expression of IL-10, hemodynamic, myocardial structure, and function. These indicate that lipoxin A4 mitigates postresuscitation myocardial IRI in which anti-inflammation and suppression of NF-κB activation may play an important role.
authors.affiliation: Renmin Hospital of Wuhan University, 238 JieFang Road, Wuhan, 430060, People's Republic of China.
authors.forename: Zhiqiao
authors.initials: Z
authors.lastname: Chen
authors.forename: Zhe
authors.initials: Z
authors.lastname: Wu
authors.forename: Congxin
authors.initials: C
authors.lastname: Huang
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Yirong
authors.initials: Y
authors.lastname: Zhou
authors.forename: Xianlong
authors.initials: X
authors.lastname: Zhou
authors.forename: Xingxing
authors.initials: X
authors.lastname: Lu
authors.forename: Lele
authors.initials: L
authors.lastname: Mao
authors.forename: Siying
authors.initials: S
authors.lastname: Li
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D005260:Female; D006323:Heart Arrest; D007249:Inflammation / Q000188:drug therapy*; D016753:Interleukin-10 / Q000096:biosynthesis; D053583:Interleukin-1beta / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D044045:Lipoxins / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism; D016328:NF-kappa B / Q000096:biosynthesis / Q000378:metabolism; D011817:Rabbits; D051996:Transcription Factor RelA / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D053583:Interleukin-1beta; D015850:Interleukin-6; D044045:Lipoxins; D016328:NF-kappa B; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; C040527:lipoxin A4; D016753:Interleukin-10